A sign of Japanese pharmaceutical company Daiichi Sankyo Co., Ltd. is seen at the company's head office in Tokyo July 17, 2009. REUTERS/Stringer (JAPAN BUSINESS HEALTH)
(Reuters) – A jury in Marshall, Texas, on Friday awarded biotech company Seagen Inc nearly $42 million from Japanese rival drugmaker Daiichi Sankyo Co over claims that Daiichi and AstraZeneca plc's breast-cancer drug Enhertu violates Seagen's patent rights.
The jury found that Daiichi willfully infringed a patent owned by Washington State-based Seagen that covers technology for delivering chemotherapy drugs to cancer cells.
Daiichi said in a statement that it disagreed with the verdict and was exploring its options, including potential post-trial motions and an appeal. It also said the U.S. Patent and Trademark Office granted its request to review the patent's validity on Thursday.
Seagen said it was pleased with the verdict and would request additional royalties on future sales of Enhertu in the United States until the patent expires in 2024.
Cambridge, U.K.-based AstraZeneca, which co-developed Enhertu and markets it in the United States with Daiichi, did not immediately respond to a request for comment. The jury did not find it responsible for any of the $41.8 million award.
Enhertu is considered a potential multi-billion dollar drug to treat metastatic breast cancer. AstraZeneca reported that sales of Enhertu outside of Japan were worth $426 million last year.
Seagen filed the lawsuit in the U.S. District Court for the Eastern District of Texas in 2020, claiming Enhertu works in the same way as its patent related to antibody-drug conjugates, which use antibodies to target cancer cells with chemotherapy drugs.
U.S. District Judge Rodney Gilstrap presided over the trial, which began Monday.
The case is Seagen Inc v. Daiichi Sankyo Co, U.S. District Court for the Eastern District of Texas, No. 2:20-cv-00337.
For Seagen: Michael Jacobs of Morrison & Foerster
For AstraZeneca: David Berl of Williams & Connolly
For Daiichi Sankyo: Preston Ratliff of Paul Hastings
Our Standards: The Thomson Reuters Trust Principles.
Washington-based correspondent covering court cases, trends, and other developments in intellectual property law, including patents, trademarks, copyrights, and trade secrets. Previous experience at Bloomberg Law, Thomson Reuters Practical Law and work as an attorney.
Sign up to our legal newsletter for a smart look at the day's headlines concerning the practice of law.
Subscribe to our newsletter to get all the news you need to start your day.
Thomson Reuters Institute
Anders Spile
Thomson Reuters Institute
Shonette Gaston
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2022 Reuters. All rights reserved